Advancing valuable commercial opportunity in stiff person syndrome (SPS) following landmark registrational data; Biologics License Application ...

Company expects preliminary unaudited AUCATZYL® net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately ...

Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single weight-based dose IND amendment ...

The 2025 American Society of Hematology (ASH) meeting in December presented a clear message: scientific innovation and ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today provided corporate ...

Idiopathic nephrotic syndrome (INS), characterized by heavy proteinuria, edema and hypoalbuminemia, is the most common glomerular disease in childhood (1). Common histologic variants are minimal ...

The fact that the complement system is activated during immune-complex glomerular disease has been known for nearly 50 years. Detection of complement deposition in the glomerulus using immunochemistry ...

The National Testing Agency (NTA) has issued the subject wise NEET 2026 syllabus on this website soon after the NMC released ...

Roche's anti-CD20 antibody Gazyva has been on the market for more than a decade as a treatment for blood cancer, but could see a new lease of life if it gets FDA approval to treat kidney disease ...

People who struggle with imposter syndrome believe that they are undeserving of their achievements and the high esteem in which they are, in fact, generally held. They feel that they aren’t as ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...